C-myc expression in cell lines derived from chronic myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Haematologica

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15003904
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Occult hepatitis B virus infection: implications in transfusion

  2004cited by this paper
• Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

  2004cited by this paper
• Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.

  2003cited by this paper
• Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002

  2003cited by this paper
• Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.

  2003cited by this paper
• Chronic myeloid leukemia--advances in biology and new approaches to treatment.

  2003cited by this paper
• Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies

  2003cited by this paper
• Nucleic acid testing for emerging viral infections

  2002cited by this paper
• Residual risk of transfusion‐transmitted HCV and HIV infections by antibody‐screened blood in Italy

  2002cited by this paper
• Jak2 is involved in c-Myc induction by Bcr-Abl

  2002cited by this paper
• Viral marker rates among blood donors before and after the terrorist attacks on the United States on September 11, 2001

  2002cited by this paper
• Persistence of HTLV-I in blood components after leukocyte depletion.

  2002cited by this paper
• Recent advancements in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• Contributions of Myc to tumorigenesis.

  2002cited by this paper
• Estimated risk of transfusion‐transmitted viral infections in Spain

  2002cited by this paper
• Blood Products: A Significant Risk Factor for Long-Term Catheter-Related Bloodstream Infections in Cancer Patients

  2001cited by this paper
• Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma.

  2001cited by this paper
• Genomic screening for blood-borne viruses in transfusion settings.

  2000cited by this paper
• Transmission of tick‐borne agents of disease by blood transfusion: a review of known and potential risks in the United States

  2000cited by this paper
• Prevention of transfusion-associated graft-versus-host disease by photochemical treatment.

  1999cited by this paper
• An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

  1999cited by this paper
• Apoptosis and mitotic arrest are two independent effects of the protein phosphatases inhibitor okadaic acid in K562 leukemia cells.

  1999cited by this paper
• c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia.

  1998cited by this paper
• SAFER THAN EVER

  1997cited by this paper
• Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long‐wavelength ultraviolet light

  1997cited by this paper
• Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors.

  1997cited by this paper
• Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase.

  1997cited by this paper
• Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells.

  1995cited by this paper
• A prospective study of symptomatic bacteremia following platelet transfusion and of its management

  1994cited by this paper
• Dominant negative MYC blocks transformation by ABL oncogenes.

  1992cited by this paper
• Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

  1991cited by this paper

• Anti-Leukemic Effects of Small Molecule Inhibitor of c-Myc (10058-F4) on Chronic Myeloid Leukemia Cells

  2024cites this paper
• ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1

  2023cites this paper
• New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges

  2021cites this paper
• Recent advances in searching c-Myc transcriptional cofactors during tumorigenesis

  2018cites this paper
• Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo

  2016cites this paper
• NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells.

  2016cites this paper
• MYC oncogene in myeloid neoplasias

  2013cites this paper
• Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements

  2013cites this paper
• MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1

  2013cites this paper
• Cip 1 confers resistance to imatinib in human chronic myeloid leukemia cells

  2012cites this paper
• Antitumor effects of imatinib mesylate and synergistic cytotoxicity with an arsenic compound in neuroblastoma cell lines.

  2011cites this paper
• MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib

  2011cites this paper
• SKP2 Oncogene Is a Direct MYC Target Gene and MYC Down-regulates p27KIP1 through SKP2 in Human Leukemia Cells*

  2011cites this paper
• p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells.

  2010cites this paper
• Myc roles in hematopoiesis and leukemia.

  2010cites this paper
• Selective activation of apoptosis by a novel set of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones through a Myc-dependent pathway.

  2009cites this paper
• Regulation of transferrin receptor 2 in human cancer cell lines.

  2009cites this paper
• Chloramphenicol induces abnormal differentiation and inhibits apoptosis in activated T cells.

  2008cites this paper
• Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc

  2006cites this paper
• Effects of the antitumoural dequalinium on NB4 and K562 human leukemia cell lines. Mitochondrial implication in cell death.

  2005cites this paper